{"id":846,"date":"2026-06-26T15:46:32","date_gmt":"2026-06-26T13:46:32","guid":{"rendered":"https:\/\/studienportal-endometriumkrebs.de\/destiny-endometrial01\/"},"modified":"2026-07-22T12:01:23","modified_gmt":"2026-07-22T10:01:23","slug":"destiny-endometrial01","status":"publish","type":"post","link":"https:\/\/studienportal-endometriumkrebs.de\/tr\/destiny-endometrial01\/","title":{"rendered":"DESTINY-ENDOMETRIAL01"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"846\" class=\"elementor elementor-846 elementor-601\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-2c69b70e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2c69b70e\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4986c601\" data-id=\"4986c601\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6588708f elementor-widget elementor-widget-heading\" data-id=\"6588708f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\"><strong>DESTINY-ENDOMETRIAL01<\/strong><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-35c6b8be elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"35c6b8be\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-590f42d8\" data-id=\"590f42d8\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1514f64a headline elementor-widget elementor-widget-heading\" data-id=\"1514f64a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">\u0130LER\u0130 EVRE VEYA N\u00dcKS EDEN GEB\u00c4RMUTTERSCHLEIMHAUTKREBS (ENDOMETR\u0130YUM KANSER\u0130) OLAN HASTALARDA TRASTUZUMAB DERUXTECAN (T-DXD) VE RILVEGOSTOMIG VEYA PEMBROLIZUMAB KOMB\u0130NASYONUNA Y\u00d6NEL\u0130K TEDAV\u0130 \u00c7ALI\u015eMASI<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2d47951f elementor-widget elementor-widget-text-editor\" data-id=\"2d47951f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>DESTINY-Endometrial01; t\u00fcm\u00f6r h\u00fccreleri HER2&#8217;yi a\u015f\u0131r\u0131 eksprese eden ve pMMR durumuna sahip olan, ileri evre veya n\u00fcks eden rahim i\u00e7i kanseri (endometriyum kanseri) olan hastalar i\u00e7in yeni bir tedavi se\u00e7ene\u011fini inceleyen k\u00fcresel, randomize (belirli bir hasta i\u00e7in tedavi atamas\u0131n\u0131n rastgele yap\u0131ld\u0131\u011f\u0131) bir Faz 3 \u00e7al\u0131\u015fmad\u0131r. Bu kapsamda, <em>Trastuzumab deruxtecan<\/em> ilac\u0131 ile yap\u0131lan iki yeni kombinasyon tedavisi (Rilvegostomig veya Pembrolizumab ile T-DXd), kemoterapi ve imm\u00fcnoterapiden olu\u015fan mevcut standart tedavi ile kar\u015f\u0131la\u015ft\u0131r\u0131lmaktad\u0131r. Ama\u00e7, yeni tedavilerin hastal\u0131\u011f\u0131n ilerlemesini daha uzun s\u00fcre engelleyip engelleyemeyece\u011fini bulmakt\u0131r.  <\/p><h2><strong>Bu \u00e7al\u0131\u015fmada ne inceleniyor?<\/strong><\/h2><p>Endometriyum kanserleri, rahmin en s\u0131k g\u00f6r\u00fclen kanser t\u00fcrleri aras\u0131ndad\u0131r.<\/p><p>\u0130lk te\u015fhis an\u0131nda ileri evre veya n\u00fcks eden hastal\u0131\u011f\u0131 olan hastalarda standart tedavi genellikle kemoterapi ve imm\u00fcnoterapi kombinasyonundan olu\u015fur. Bununla birlikte, bir\u00e7ok hastada zamanla hastal\u0131\u011f\u0131n ilerlemesi g\u00f6r\u00fclmektedir, bu nedenle yeni tedavi yakla\u015f\u0131mlar\u0131na ihtiya\u00e7 duyulmaktad\u0131r. <\/p><p>\u00c7al\u0131\u015fma, t\u00fcm\u00f6rleri insan epidermal b\u00fcy\u00fcme fakt\u00f6r\u00fc resept\u00f6r\u00fc 2 (HER2) ta\u015f\u0131yan hastalara y\u00f6neliktir. <strong>HER2<\/strong>, t\u00fcm\u00f6r h\u00fccrelerinin y\u00fczeyinde bulunan ve kanser h\u00fccresine b\u00fcy\u00fcme sinyalleri iletebilen bir proteindir. Baz\u0131 endometriyum kanserlerinde, hedefe y\u00f6nelik tedaviler i\u00e7in bir sald\u0131r\u0131 noktas\u0131 olarak kullan\u0131labilecek artm\u0131\u015f bir HER2 varl\u0131\u011f\u0131 bulunur. <\/p><p>Ayr\u0131ca, t\u00fcm\u00f6rlerin <strong>pMMR durumu<\/strong> (proficient Mismatch Repair) sergilemesi gerekir. Bu, genetik materyaldeki hatalar i\u00e7in bu onar\u0131m sisteminin temel olarak \u00e7al\u0131\u015ft\u0131\u011f\u0131 anlam\u0131na gelir. Bu t\u00fcm\u00f6rler, imm\u00fcnoterapilere genellikle onar\u0131m sistemi bozuk olan (dMMR) t\u00fcm\u00f6rlerden daha az yan\u0131t verirler, bu nedenle yeni tedavi stratejileri ara\u015ft\u0131r\u0131lmaktad\u0131r.  <\/p><p>Bu \u00e7al\u0131\u015fmada di\u011ferlerinin yan\u0131 s\u0131ra <em>Trastuzumab deruxtecan<\/em> (T-DXd) kullan\u0131lmaktad\u0131r. Bu, antikor-ila\u00e7 konjugat\u0131 (ADC) olarak adland\u0131r\u0131lan bir maddedir. Antikor, t\u00fcm\u00f6r h\u00fccrelerinin y\u00fczeyindeki HER2&#8217;yi hedefli olarak tan\u0131r ve ard\u0131ndan kanser h\u00fccresini yok etmek i\u00e7in i\u00e7ine bir h\u00fccre zehri aktar\u0131r.  <\/p><p>T-DXd bu \u00e7al\u0131\u015fmada ya bir imm\u00fcnoterapi olan <em>Pembrolizumab<\/em> ile ya da <em>Rilvegostomig<\/em> ile kombine edilir. <em>Rilvegostomig<\/em>, v\u00fccudun t\u00fcm\u00f6re kar\u015f\u0131 savunmas\u0131n\u0131 g\u00fc\u00e7lendirmek i\u00e7in ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin \u00e7e\u015fitli mekanizmalar\u0131n\u0131 ayn\u0131 anda etkilemeyi ama\u00e7layan yeni bir imm\u00fcnoterap\u00f6tik etkendir.<\/p><h2><strong>\u00c7al\u0131\u015fman\u0131n amac\u0131 nedir?<\/strong><\/h2><p>\u00c7al\u0131\u015fman\u0131n temel amac\u0131, <em>Trastuzumab deruxtecan<\/em>&#8216;\u0131n <em>Rilvegostomig<\/em> veya <em>Pembrolizumab<\/em> ile kombinasyonunun, hastal\u0131\u011f\u0131n ilerlemesini kemoterapi ve <em>Pembrolizumab<\/em>&#8216;dan olu\u015fan mevcut standart tedaviden daha uzun s\u00fcre engelleyip engelleyemeyece\u011fini incelemektir.<\/p><p>Buna ek olarak, yeni tedavi stratejilerinin genel sa\u011fkal\u0131m s\u00fcresi \u00fczerinde etkili olup olmad\u0131\u011f\u0131 ve tedavilerin ne kadar iyi tolere edildi\u011fi incelenmektedir. Tedavi s\u0131ras\u0131nda ya\u015fam kalitesi ve hastalar taraf\u0131ndan bildirilen \u015fikayetler de ara\u015ft\u0131r\u0131lmaktad\u0131r. <\/p><h2><strong>\u00c7al\u0131\u015fman\u0131n ak\u0131\u015f\u0131 nas\u0131ld\u0131r?<\/strong><\/h2><p>\u00c7al\u0131\u015fmaya kat\u0131lan hastalar, rastgelelik ilkesine g\u00f6re \u00fc\u00e7 tedavi kolundan birine atan\u0131r:<\/p><p><span style=\"text-decoration: underline;\">Kol 1:<\/span><br\/><em>Trastuzumab deruxtecan<\/em> + <em>Rilvegostomig<\/em>, her \u00fc\u00e7 haftada bir inf\u00fczyon olarak.<\/p><p><span style=\"text-decoration: underline;\">Kol 2:<\/span><br\/><em>Trastuzumab deruxtecan<\/em> + <em>Pembrolizumab<\/em>, her \u00fc\u00e7 haftada bir inf\u00fczyon olarak.<\/p><p><span style=\"text-decoration: underline;\">Kol 3:<\/span><br\/>6 tedavi d\u00f6ng\u00fcs\u00fc boyunca <em>Karboplatin<\/em> ve <em>Paklitaksel<\/em> + <em>Pembrolizumab<\/em> ile kemoterapiden olu\u015fan mevcut standart tedavi. Ard\u0131ndan, 14 d\u00f6ng\u00fcye kadar idame tedavisi olarak <em>Pembrolizumab<\/em> verilmeye devam edilir. <\/p><p>Tedavi, hastal\u0131k ilerleyene, kabul edilemez yan etkiler ortaya \u00e7\u0131kana veya tedavinin kesilmesi i\u00e7in ba\u015fka nedenler olu\u015fana kadar t\u00fcm \u00e7al\u0131\u015fma kollar\u0131nda s\u00fcrd\u00fcr\u00fcl\u00fcr.<\/p><p style=\"margin: 0px 0px 20px; font-family: Roboto, Arial, sans-serif; color: #545454; font-size: 16.8px;\">T\u00fcm \u00e7al\u0131\u015fma boyunca, tedavinin etkisini, olas\u0131 yan etkileri ve hastalar\u0131n genel sa\u011fl\u0131k durumunu izlemek i\u00e7in d\u00fczenli kontroller yap\u0131l\u0131r.<\/p><h2><strong>Riskler var m\u0131?<\/strong><\/h2><p><span style=\"color: #545454; font-family: Roboto, Arial, sans-serif; font-size: 16.8px;\">Kat\u0131l\u0131mla ilgili olas\u0131 riskler veya yan etkiler hakk\u0131nda doktorunuz taraf\u0131ndan bir bilgilendirme g\u00f6r\u00fc\u015fmesi kapsam\u0131nda bilgilendirileceksiniz.<\/span><\/p><h2><strong>Kat\u0131l\u0131m Ko\u015fullar\u0131:<\/strong><\/h2><p>Bu \u00e7al\u0131\u015fmaya a\u015fa\u011f\u0131daki kriterleri kar\u015f\u0131layan 18 ya\u015f ve \u00fczeri kad\u0131nlar kat\u0131labilir:<\/p><ul><li>Onaylanm\u0131\u015f epitelyal endometriyum kanseri te\u015fhisi. Sarkomlar hari\u00e7 t\u00fcm histolojik tipler kabul edilir (karsinosarkomlar kabul edilir). <\/li><li>\u0130lk te\u015fhis an\u0131nda ileri evre endometriyum kanseri (Evre III\/IV) veya endometriyum kanserinin ilk n\u00fcks\u00fc<\/li><li>Merkezi olarak kan\u0131tlanm\u0131\u015f pozitif HER2 durumu (IHC 3+ veya 2+)<\/li><li>Onaylanm\u0131\u015f pMMR durumu (\u00e7al\u0131\u015fan MMR onar\u0131m mekanizmas\u0131)<\/li><li>Hastal\u0131k i\u00e7in daha \u00f6nce sistemik tedavi uygulanmam\u0131\u015f olmal\u0131d\u0131r; \u015funlar hari\u00e7: adjuvan\/neoadjuvan kemoterapi veya radyokemoterapi (n\u00fcks durumunda, hastal\u0131\u011f\u0131n yeniden ortaya \u00e7\u0131kmas\u0131 veya ilerlemesi son kemoterapi dozundan \u2265 6 ay sonra ger\u00e7ekle\u015fmi\u015f olmal\u0131d\u0131r), adjuvan\/neoadjuvan durumda <em>Trastuzumab<\/em> tedavisi ve \u00f6nceki radyoterapiye izin verilir<\/li><li>Anti-PD-1\/PD-L1\/PD-L2 ve anti-CTLA-4 antikorlar\u0131 ile terap\u00f6tik kanser a\u015f\u0131lar\u0131 dahil (ancak bunlarla s\u0131n\u0131rl\u0131 olmamak \u00fczere) ADC&#8217;ler veya imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri ile daha \u00f6nce tedavi yap\u0131lm\u0131\u015f olmas\u0131na izin verilmez.<\/li><\/ul><p>Buna ek olarak, \u00e7al\u0131\u015fmaya kat\u0131l\u0131m i\u00e7in kar\u015f\u0131lanmas\u0131 gereken ba\u015fka kriterler de bulunmaktad\u0131r. Daha fazla bilgiyi tedavinizi y\u00fcr\u00fcten doktorlar\u0131n\u0131zdan alabilirsiniz. <\/p><p>\u00c7al\u0131\u015fma hakk\u0131nda daha fazla bilgi ve kat\u0131l\u0131m\u0131n m\u00fcmk\u00fcn oldu\u011fu merkezler \u00e7al\u0131\u015fma ana sayfas\u0131nda bulunabilir: https:\/\/www.astrazenecaclinicaltrials.com\/study\/D781DC00001\/<\/p><p style=\"margin: 0px 0px 20px; font-family: Roboto, Arial, sans-serif; color: #545454; font-size: 16.8px;\"><strong style=\"font-weight: bold; font-size: 16.8px;\">Bu \u00e7al\u0131\u015fma \u015fu kurum taraf\u0131ndan y\u00fcr\u00fct\u00fclmektedir:<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-7112f47 e-grid e-con-boxed e-con e-parent\" data-id=\"7112f47\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ba56cd8 elementor-widget elementor-widget-image\" data-id=\"ba56cd8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"500\" height=\"500\" src=\"https:\/\/studienportal-endometriumkrebs.de\/wp-content\/uploads\/Astrazeneca-1.png\" class=\"attachment-large size-large wp-image-847\" alt=\"\" srcset=\"https:\/\/studienportal-endometriumkrebs.de\/wp-content\/uploads\/Astrazeneca-1.png 500w, https:\/\/studienportal-endometriumkrebs.de\/wp-content\/uploads\/Astrazeneca-1-300x300.png 300w, https:\/\/studienportal-endometriumkrebs.de\/wp-content\/uploads\/Astrazeneca-1-150x150.png 150w\" sizes=\"(max-width: 500px) 100vw, 500px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-003554c elementor-widget elementor-widget-image\" data-id=\"003554c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"625\" height=\"351\" src=\"https:\/\/studienportal-endometriumkrebs.de\/wp-content\/uploads\/Daiichi-Sankyo.png\" class=\"attachment-large size-large wp-image-848\" alt=\"\" srcset=\"https:\/\/studienportal-endometriumkrebs.de\/wp-content\/uploads\/Daiichi-Sankyo.png 830w, https:\/\/studienportal-endometriumkrebs.de\/wp-content\/uploads\/Daiichi-Sankyo-300x168.png 300w, https:\/\/studienportal-endometriumkrebs.de\/wp-content\/uploads\/Daiichi-Sankyo-768x431.png 768w, https:\/\/studienportal-endometriumkrebs.de\/wp-content\/uploads\/Daiichi-Sankyo-624x350.png 624w\" sizes=\"(max-width: 625px) 100vw, 625px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-8042ad0 e-flex e-con-boxed e-con e-parent\" data-id=\"8042ad0\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2e15ddd elementor-widget elementor-widget-button\" data-id=\"2e15ddd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/iuvando.de\/kontakt\/\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-arrow-right\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M190.5 66.9l22.2-22.2c9.4-9.4 24.6-9.4 33.9 0L441 239c9.4 9.4 9.4 24.6 0 33.9L246.6 467.3c-9.4 9.4-24.6 9.4-33.9 0l-22.2-22.2c-9.5-9.5-9.3-25 .4-34.3L311.4 296H24c-13.3 0-24-10.7-24-24v-32c0-13.3 10.7-24 24-24h287.4L190.9 101.2c-9.8-9.3-10-24.8-.4-34.3z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Kat\u0131l\u0131m durumunu kontrol ettirin<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>DESTINY-ENDOMETRIAL01 \u0130LER\u0130 EVRE VEYA N\u00dcKS EDEN GEB\u00c4RMUTTERSCHLEIMHAUTKREBS (ENDOMETR\u0130YUM KANSER\u0130) OLAN HASTALARDA TRASTUZUMAB DERUXTECAN (T-DXD) VE RILVEGOSTOMIG VEYA PEMBROLIZUMAB KOMB\u0130NASYONUNA Y\u00d6NEL\u0130K TEDAV\u0130 \u00c7ALI\u015eMASI DESTINY-Endometrial01; t\u00fcm\u00f6r h\u00fccreleri HER2&#8217;yi a\u015f\u0131r\u0131 eksprese eden ve pMMR durumuna sahip olan, ileri evre veya n\u00fcks eden rahim i\u00e7i kanseri (endometriyum kanseri) olan hastalar i\u00e7in yeni bir tedavi se\u00e7ene\u011fini inceleyen k\u00fcresel, randomize (belirli [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[37],"tags":[],"class_list":["post-846","post","type-post","status-publish","format-standard","hentry","category-calismalar"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/comments?post=846"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/846\/revisions"}],"predecessor-version":[{"id":849,"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/846\/revisions\/849"}],"wp:attachment":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/media?parent=846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/categories?post=846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/tags?post=846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}